Is GH for adult growth hormone deficiency now legal?

[Deleted member 43589]

I am hearing that in 2020, the FDA, at the request of Novo Nordisk (pharma), approved a product called Sogroya (somapacitan) for adults with growth hormone deficiency. Sogroya is the first human growth hormone (hGH) therapy that adult patients only take once a week by sub-q injection; other FDA-approved hGH formulations for adults with growth hormone deficiency must be administered daily. If it is approve by the FDA, insurance will cover the use pfthis product.

FDA approves weekly therapy for adult growth hormone deficiency

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life. Daily subcutaneous injections ...

www.ncbi.nlm.nih.gov

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. - Full Text View - ClinicalTrials.gov

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. - Full Text View.

classic.clinicaltrials.gov

Drug Trial Snapshot: SOGROYA

SOGROYA is a drug for replacement of growth hormone in adults with growth hormone deficiency (GHD).

www.fda.gov

WOW!

https://www.goodrx.com/sogroya?ppid=2

This product is also in the tubes:

What do we do now that the long-acting growth hormone is here?

In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone deficiency ...

www.ncbi.nlm.nih.gov